-
2022-500609-42-00
4
2023-02-24
Anemia Due to Lower-Risk Myelodysplastic Syndromes
-
2024-515830-34-00
5
2023-02-14
Congenital antithrombin deficiency
-
2023-509672-42-00
5
2023-02-02
GRIN-related neurodevelopmental disorder
-
2022-501073-40-00
6
2023-01-27
Type 2 Diabetes
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-500391-62-00
9
2023-01-19
Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2023-504226-18-00
5
2022-11-30
NMDAR or LGI1 mediated autoimmune Encephalitis
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2023-508349-42-00
3
2022-10-18
Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 k
-
2023-503795-24-00
7
2022-09-16
Avanced Non-Small Cell Lung Cancer
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2024-513185-19-00
9
2022-07-13
Extensive stage small cell lung cancer (ES-SCLC)
-
2024-512119-34-00
4
2022-06-20
MSI-H/dMMR metastatic colorectal cancer
-
2022-501876-24-00
3
2022-06-17
Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
-
2023-509936-25-00
4
2022-06-09
Transplant Rejection
-
2023-509715-91-00
5
2022-05-06
Fabry’s disease
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-505638-82-00
5
2022-01-12
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2023-509331-83-00
5
2021-07-28
complement 3 glomerulopathy
-
2023-504084-17-00
9
2021-07-12
ALK fusion-positive extracranial solid or primary CNS tumors who have
-
2023-506145-38-00
3
2021-05-11
Treatment of participants with MF, MDS, ET, or MDS/MPN
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies